Luz Jubierre

735 total citations
8 papers, 440 citations indexed

About

Luz Jubierre is a scholar working on Molecular Biology, Cancer Research and Neurology. According to data from OpenAlex, Luz Jubierre has authored 8 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Cancer Research and 3 papers in Neurology. Recurrent topics in Luz Jubierre's work include MicroRNA in disease regulation (4 papers), Neuroblastoma Research and Treatments (3 papers) and Protein Degradation and Inhibitors (3 papers). Luz Jubierre is often cited by papers focused on MicroRNA in disease regulation (4 papers), Neuroblastoma Research and Treatments (3 papers) and Protein Degradation and Inhibitors (3 papers). Luz Jubierre collaborates with scholars based in Spain, United States and Japan. Luz Jubierre's co-authors include Miguel F. Segura, Aroa Soriano, Josep Roma, Soledad Gallego, Joan Sánchez-de-Toledo, Eva Hernando, Avital Gaziel‐Sovran, Pilar González‐Gómez, Michael Ohlmeyer and Guangtao Zhang and has published in prestigious journals such as Cancer Research, Oncogene and Cell Death and Disease.

In The Last Decade

Luz Jubierre

8 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luz Jubierre Spain 7 377 142 93 67 62 8 440
John F. Schwerkoske United States 8 174 0.5× 54 0.4× 110 1.2× 30 0.4× 26 0.4× 13 343
Giulia Cheloni United States 10 316 0.8× 173 1.2× 63 0.7× 184 2.7× 13 0.2× 22 483
Kristi Allen United States 5 386 1.0× 304 2.1× 65 0.7× 30 0.4× 11 0.2× 7 455
Julie Ross Canada 10 373 1.0× 51 0.4× 86 0.9× 67 1.0× 11 0.2× 14 497
Laura García-Ortí Spain 5 311 0.8× 77 0.5× 58 0.6× 161 2.4× 7 0.1× 6 397
Shaojie Wu China 6 208 0.6× 96 0.7× 145 1.6× 32 0.5× 7 0.1× 21 332
Dan Williamson United Kingdom 6 205 0.5× 79 0.6× 78 0.8× 68 1.0× 27 0.4× 8 393
Rodolphe F. Taby United States 6 572 1.5× 160 1.1× 46 0.5× 150 2.2× 9 0.1× 8 662
Fotini Vogiatzi Germany 8 173 0.5× 55 0.4× 150 1.6× 19 0.3× 12 0.2× 15 294
Nerea Marcotegui Spain 10 283 0.8× 75 0.5× 45 0.5× 160 2.4× 7 0.1× 12 374

Countries citing papers authored by Luz Jubierre

Since Specialization
Citations

This map shows the geographic impact of Luz Jubierre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luz Jubierre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luz Jubierre more than expected).

Fields of papers citing papers by Luz Jubierre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luz Jubierre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luz Jubierre. The network helps show where Luz Jubierre may publish in the future.

Co-authorship network of co-authors of Luz Jubierre

This figure shows the co-authorship network connecting the top 25 collaborators of Luz Jubierre. A scholar is included among the top collaborators of Luz Jubierre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luz Jubierre. Luz Jubierre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Jubierre, Luz, Carlos Jiménez, Aroa Soriano, et al.. (2018). Targeting of epigenetic regulators in neuroblastoma. Experimental & Molecular Medicine. 50(4). 1–12. 38 indexed citations
2.
Feliciano, Andrea, Yoelsis Garcia‐Mayea, Luz Jubierre, et al.. (2017). miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer. Cell Death and Disease. 8(10). e3141–e3141. 75 indexed citations
3.
Segura, Miguel F., Luz Jubierre, SiDe Li, et al.. (2017). Krüppel-like factor 4 (KLF4) regulates the miR-183~96~182 cluster under physiologic and pathologic conditions. Oncotarget. 8(16). 26298–26311. 13 indexed citations
4.
Jubierre, Luz, Aroa Soriano, Stephan P. Tenbaum, et al.. (2016). BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene. 35(39). 5179–5190. 52 indexed citations
5.
Soriano, Aroa, Luz Jubierre, Xiangyu Zhou, et al.. (2016). MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. Oncotarget. 7(8). 9271–9287. 26 indexed citations
6.
Almazán-Moga, Ana, Josep Roma, Luz Jubierre, et al.. (2014). Optimization of rhabdomyosarcoma disseminated disease assessment by flow cytometry. Cytometry Part A. 85(12). 1020–1029. 5 indexed citations
7.
Soriano, Aroa, Luz Jubierre, Ana Almazán-Moga, et al.. (2013). microRNAs as pharmacological targets in cancer. Pharmacological Research. 75. 3–14. 47 indexed citations
8.
Segura, Miguel F., Bárbara Fontanals-Cirera, Avital Gaziel‐Sovran, et al.. (2013). BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy. Cancer Research. 73(20). 6264–6276. 184 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026